Hangzhou Tian-Mu-Shan Stock Hits Day High with 11.69% Surge

Hangzhou Tian-Mu-Shan Pharmaceutical Enterprise Co., Ltd. has experienced a significant surge in its stock performance, gaining 11.69% on February 24, 2026. The stock reached an intraday high of CNY 22.46, marking a notable achievement for the small-cap company in the pharmaceuticals and biotechnology sector. In terms of performance metrics, Hangzhou Tian-Mu-Shan has shown impressive growth over various time frames. Over the past year, the stock has soared by 130.83%, significantly outperforming the China Shanghai Composite, which recorded a gain of only 22.49%. The company's year-to-date performance stands at 29.75%, again surpassing the broader market's 2.85% increase. Despite these positive short-term trends, the company faces challenges in its long-term fundamentals, with a Return on Capital Employed (ROCE) averaging 5.37%. Additionally, the company has a high Debt to Equity ratio of 2.33, indicating a reliance on debt financing. Investors may want to consider these factors as they assess the company's market position and financial health.